Sign in

If the govt. acts now, India can eliminate hepatitis B by 2080: experts

Viral hepatitis B affects close to 45 million people in India

Published on: Jul 27, 2016, 18:06:25 IST
Share
Share via
  • facebook
  • twitter
  • linkedin
  • whatsapp
Copy link
  • copy link

New Delhi: If the government acts now, India will be able to eliminate hepatitis B, a viral infection that can lead to permanent liver damage and even cancer, by 2080, say experts on the occasion of World Hepatitis Day. The global target is 2030.

WHO observes July 28 as World Hepatitis Day. (Shutterstock)
WHO observes July 28 as World Hepatitis Day. (Shutterstock)

World Health Organisation (WHO) observes the day on July 28 each year, and the theme for this year is elimination.

Nearly 400 million people are affected with viral hepatitis globally that are broadly categorised as water-borne A&E and blood-borne B & C.

While hepatitis viruses A&E produce self-limiting symptoms, the main causes of concern are blood-borne viral infections—HBV & HCV that lead to chronic liver diseases. The infection, if not handled in time, may progress even to liver cancer over a period of time.

An estimated 54 million people in India are affected with viral hepatitis HBV & HCV— about 45 million with HBV and 8.7 million with HCV.

Hepatitis C has a cure, and 90% of people can get cured after three months of treatment and in six months 100% can be cured.

Hence, focus is on hepatitis B, and expanding vaccination programmes for HBV is seen among the key approaches to elimination.

The HBV vaccine provides more than 99% protection.

“Since maximum transmission, about 95%, happens from mother-to-baby, vaccination could be the key. The vaccine is a part of National Immunisation Programme since 2013, but the coverage as of now is inadequate,” said Dr SK Sarin, director, Institute of Liver and Biliary Sciences (ILBS).

Three injections over a six to 12 month period are required to provide full resistance, but government will have to ensure compliance.

Dr Sarin says it will take at least 65 years for India to eliminate HBV, and it would require a three pronged strategy— to treat people affected with HBV free of cost; vaccinate newborns and adults; screen people who received blood transfusion or surgery before 2001.

“Our average age is around 65 years, so we need to treat free of cost those who are currently infected with HBV to prevent transmission. It’s one tablet a day for life, which can be included in the essential drug list,” he said.

For vaccination, Dr Ajay Bhalla, gastroenterology, Fortis Hospital-Noida, says, “Not just the newborns, but those up to 18 years of age and also people among high risk category should get vaccinated.”

However, getting screened is important as 95% of those infected are not aware of it.

People who underwent blood transfusion or surgery before 2001 should especially get tested because the blood wasn’t screened for hepatitis before that.

“If the government gets a bit proactive and sort of pledges that all newborns be vaccinated then it is possible to eliminate the disease by 2080,” Dr Sarin said.

Hepatitis B is responsible for 1.4 million deaths each year, which is more than 2.7 million deaths due to HIV/AIDS and malaria and TB combined.

Viral hepatitis in figures

400 million: people affected with viral hepatitis globally

1.4 million: people killed each year globally (viruses B and C mostly)

5%: people are aware of their infection

1%: have access to treatment

Hepatitis B (HBV) facts and figures

*Viruses: water-borne A&E and blood-borne B&C

*Viruses B & C cause chronic hepatitis

*Hepatitis B is 100 times more contagious than HIV

*Transmitted through all body fluids— sweat, saliva, semen, urine & blood

*Has a vaccine but no cure

*Vaccination offers >99% protection

*350 million: persons worldwide infected with HBV

*0.3%: affected adults

*45 million: HBV carriers in India

*1 million: deaths worldwide each year related to HBV complications

*75%: chronic carriers are Asians

  • Rhythma Kaul
    ABOUT THE AUTHOR
    Rhythma Kaul

    Rhythma Kaul is the national health editor of the Hindustan Times. She has been reporting on public health, medicine, and medical research, with a particular focus on how government decisions and health system reforms shape people’s lives. Rhythma has over 25 years of journalistic experience. She joined Hindustan Times in 2008, and has since covered everything from pandemics and infectious diseases to cutting‑edge medical research and climate‑related health challenges. Her stories routinely track the work of the Ministry of Health and Family Welfare, department of pharmaceuticals, and key national health programmes, making complex medical science and policy accessible to a wide audience. One of her prominent news breaks has been the 2012 Baby Falak case: A two-year-old brutally battered baby girl was admitted to AIIMS-Delhi with severe head injuries, multiple fractures, human bite marks, and burns. The police investigation revealed this to be a case of multi-state human-trafficking racket. She was profiled by The Wall Street Journal for breaking this story. Rhythma holds a Master’s degree from Jawaharlal Nehru University, Delhi. Prior to Hindustan Times, she worked with the India Today Group. Rhythma can be contacted at rhythma.kaul@hindustantimes.com. Her X handle is @RamblingBrook.Read More

Get the latest India News, breaking headlines and real-time updates from across the country. Stay informed about politics, government policies, crime, weather and major national developments.